Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Molecular residual disease assessment in early-stage breast cancer

Interventional study of postoperative ctDNA in lymph-node-positive early breast cancer. The registry lists the phase as not applicable and the primary outcome as the number of participants with postoperative ctDNA detected. ClinicalTrials.gov lists the study as recruiting.

UNC Lineberger Comprehensive Cancer Center